Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
RARE on Nasdaq
Shares outstanding
95,963,102
Price per share
$23.00
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
95,477,293
Total reported value
$2,872,224,808
% of total 13F portfolios
0.01%
Share change
+593,699
Value change
-$30,046,998
Number of holders
295
Price from insider filings
$23.00
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 8.3% $239,585,319 7,964,937 FMR LLC 30 Sep 2025
BlackRock, Inc. 5.1% $163,140,305 4,820,931 BlackRock, Inc. 31 Mar 2025
SANDS CAPITAL MANAGEMENT, LLC 4.7% $145,444,422 4,298,003 SANDS CAPITAL MANAGEMENT, LLC 31 Dec 2024
WELLINGTON MANAGEMENT GROUP LLP 2.7% $83,163,255 2,457,543 Wellington Management Group LLP 31 Dec 2024

As of 30 Sep 2025, 295 institutional investors reported holding 95,477,293 shares of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE). This represents 99% of the company’s total 95,963,102 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) together control 68% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 11% 10,132,728 -0.79% 0% $304,792,459
FMR LLC 7.6% 7,283,296 +180% 0.01% $219,081,558
BlackRock, Inc. 6.7% 6,425,263 +2.7% 0% $193,271,911
JPMORGAN CHASE & CO 4.2% 4,011,429 +23% 0.01% $120,663,796
SANDS CAPITAL MANAGEMENT, LLC 3.9% 3,769,853 -4.4% 0.31% $113,397,178
STATE STREET CORP 3.8% 3,692,487 +44% 0% $111,070,009
RTW INVESTMENTS, LP 3.4% 3,258,266 +91% 1.2% $98,008,641
BAKER BROS. ADVISORS LP 2.9% 2,772,692 0% 0.6% $83,402,575
PRICE T ROWE ASSOCIATES INC /MD/ 2.4% 2,310,174 -20% 0.01% $69,491,000
JACOBS LEVY EQUITY MANAGEMENT, INC 2.3% 2,167,729 +614% 0.26% $65,205,288
SUVRETTA CAPITAL MANAGEMENT, LLC 2.1% 2,019,000 -11% 1.8% $60,731,520
WELLINGTON MANAGEMENT GROUP LLP 2% 1,945,129 +3.9% 0.01% $58,509,481
GEODE CAPITAL MANAGEMENT, LLC 1.6% 1,580,507 -7.7% 0% $47,551,518
DEUTSCHE BANK AG\ 1.6% 1,546,101 -7.2% 0.02% $46,506,718
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 1.6% 1,545,279 +6.4% 0.12% $46,482,000
Pictet Asset Management Holding SA 1.5% 1,458,187 -14% 0.04% $43,988,784
Rock Springs Capital Management LP 1.3% 1,246,341 -10% 2.2% $37,489,937
GW&K Investment Management, LLC 1.2% 1,150,169 +139% 0.31% $34,597,000
Schonfeld Strategic Advisors LLC 1.2% 1,144,589 +102% 0.24% $34,429,232
FRONTIER CAPITAL MANAGEMENT CO LLC 1.1% 1,069,098 +103% 0.29% $32,158,463
Frazier Life Sciences Management, L.P. 1% 983,715 0% 0.89% $29,590,147
Aberdeen Group plc 1% 973,656 +94% 0.05% $29,287,572
MORGAN STANLEY 0.95% 910,183 +42% 0% $27,378,343
Russell Investments Group, Ltd. 0.88% 840,451 +599% 0.03% $25,280,799
Invesco Ltd. 0.83% 794,849 +9.8% 0% $23,909,058

Institutional Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 408,423 $9,355,703 -$4,292,412 $23.00 10
2025 Q3 95,477,293 $2,872,224,808 -$30,046,998 $30.08 295
2025 Q2 94,131,376 $3,423,160,510 +$191,188,594 $36.36 307
2025 Q1 88,841,761 $3,218,912,230 +$30,616,545 $36.21 296
2024 Q4 87,497,812 $3,681,153,647 +$41,521,385 $42.07 309
2024 Q3 85,955,607 $4,772,717,045 -$110,532,026 $55.55 302
2024 Q2 88,188,346 $3,624,602,754 +$370,533,398 $41.10 271
2024 Q1 79,126,955 $3,691,777,497 -$57,749,656 $46.69 271
2023 Q4 254,995 $12,200,616 +$675,667 $47.82 4
2023 Q3 69,998,943 $2,495,206,751 +$11,050,478 $35.65 217
2023 Q2 68,829,326 $3,174,706,065 +$15,102,181 $46.13 234
2023 Q1 68,644,414 $2,752,282,615 +$26,131,494 $40.10 223
2022 Q4 67,934,602 $3,146,859,962 +$17,186,181 $46.33 219
2022 Q3 61,623,095 $2,551,540,992 -$145,131,092 $41.41 212
2022 Q2 62,104,100 $3,704,244,142 +$18,551,491 $59.66 202
2022 Q1 61,754,989 $4,483,460,176 -$41,802,077 $72.62 218
2021 Q4 67,334,441 $5,662,132,194 +$81,983,266 $84.09 215
2021 Q3 66,612,239 $6,007,303,733 +$102,035,423 $90.19 213
2021 Q2 65,392,463 $6,231,602,585 -$249,392,464 $95.35 232
2021 Q1 67,846,874 $7,727,265,104 +$49,991,404 $113.86 249
2020 Q4 67,545,737 $9,350,737,606 +$638,585,678 $138.43 244
2020 Q3 63,072,100 $5,185,727,312 -$1,949,481 $82.19 195
2020 Q2 63,110,521 $4,936,928,777 +$247,643,422 $78.22 182
2020 Q1 60,099,983 $2,669,904,425 +$85,612,131 $44.43 162
2019 Q4 55,205,870 $2,358,324,671 -$33,639,501 $42.71 160
2019 Q3 55,702,426 $2,382,914,127 -$47,549,611 $42.78 158
2019 Q2 58,716,843 $3,728,145,996 +$71,705,781 $63.50 161
2019 Q1 58,008,421 $4,023,373,718 +$543,100,082 $69.36 168
2018 Q4 50,549,541 $2,197,742,355 -$8,885,210 $43.48 154
2018 Q3 49,753,300 $3,798,512,508 +$72,495,762 $76.34 170
2018 Q2 48,810,127 $3,751,956,303 +$80,184,864 $76.87 150
2018 Q1 48,901,336 $2,493,446,451 +$367,115,489 $50.99 158
2017 Q4 43,222,558 $2,004,746,148 +$107,321,290 $46.38 154
2017 Q3 40,572,315 $2,163,180,778 -$37,010,406 $53.26 146
2017 Q2 41,008,853 $2,542,280,579 +$29,525,098 $62.11 150
2017 Q1 40,482,016 $2,743,172,220 +$147,351,890 $67.78 157
2016 Q4 41,216,638 $2,897,963,973 +$148,715,174 $70.31 168
2016 Q3 39,487,317 $2,799,413,760 +$185,324,978 $70.94 164
2016 Q2 36,359,644 $1,778,407,912 -$45,265,344 $48.91 152
2016 Q1 36,539,252 $2,312,703,412 +$79,826,584 $63.31 153
2015 Q4 35,576,350 $3,991,055,622 +$41,273,420 $112.18 164
2015 Q3 34,876,655 $3,359,085,001 +$212,205,502 $96.31 154
2015 Q2 32,244,569 $3,302,070,876 +$99,906,036 $102.39 147
2015 Q1 31,562,838 $1,958,899,846 +$230,197,763 $62.09 124
2014 Q4 27,930,073 $1,225,534,642 +$58,843,940 $43.88 99
2014 Q3 26,448,763 $1,496,999,849 +$358,139,148 $56.60 98
2014 Q2 15,622,329 $689,540,361 +$13,828,526 $44.89 80
2014 Q1 15,337,936 $730,185,000 +$729,725,256 $48.89 76